Tuberculosis (TB) caused by strains of Mycobacterium tuberculosis that are rifampicin-resistant (RR), multidrug-resistant (MDR) (strains resistant to at least isoniazid and rifampicin) or extensively drug-resistant (XDR) (MDR strains resistant to any fluoroquinolone (FQ) and to at least one second-line injectable drug (SLID): kanamycin, capreomycin or amikacin) is a major threat to TB control globally. All three groups require treatment with second-line drugs (SLDs). We previously reported that MDR- and XDR-TB in Italy occurred mostly in foreign-born persons (FBPs) , but no major information on RR, MDR or XDR trends in FBPs and Italian-born persons (IBPs) were shown. Here, we documented these trends from 2009 to 2016
Mustazzolu A., Borroni E., Cirillo D.M., Giannoni F., Iacobino A., Fattorini L., et al. (2018). Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009–2016. EUROPEAN RESPIRATORY JOURNAL, 52, 1-4 [10.1183/13993003.00070-2018].
Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009–2016
Fattorini L.;Andreoni S.;Viggiani P.;De Lorenzo S.;Farina C.;Dal Monte P.;Fabio A.;Luciano E.;Sali M.;Sanguinetti M.;Gambi A.;Costa D.;Grimaldi A.;Giraldi C.;
2018
Abstract
Tuberculosis (TB) caused by strains of Mycobacterium tuberculosis that are rifampicin-resistant (RR), multidrug-resistant (MDR) (strains resistant to at least isoniazid and rifampicin) or extensively drug-resistant (XDR) (MDR strains resistant to any fluoroquinolone (FQ) and to at least one second-line injectable drug (SLID): kanamycin, capreomycin or amikacin) is a major threat to TB control globally. All three groups require treatment with second-line drugs (SLDs). We previously reported that MDR- and XDR-TB in Italy occurred mostly in foreign-born persons (FBPs) , but no major information on RR, MDR or XDR trends in FBPs and Italian-born persons (IBPs) were shown. Here, we documented these trends from 2009 to 2016File | Dimensione | Formato | |
---|---|---|---|
2018-ERJ Mustazzolu.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per accesso libero gratuito
Dimensione
320.05 kB
Formato
Adobe PDF
|
320.05 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.